Refining the HIV Clinical Trials Enterprise

New opportunities for innovation and discovery in HIV research are within our grasp. By 2020, the National Institutes of Health will refine its science-driven HIV clinical trials enterprise to deliver the innovative, efficient results needed to turn the corner on the HIV/AIDS pandemic.

Every seven years, NIH competitively renews its funding of the HIV clinical trials networks operating in the United States and internationally. NIH began this renewal process in 2017, embarking on conversations with stakeholders and the research community to define the questions that will drive the next wave of HIV treatment and prevention innovation, and set in motion the process by which we may seek answers to those questions. These conversations have helped shape the focus and priorities of NIH’s HIV clinical trial networks through 2027.

In January 2019, NIH released six Funding Opportunity Announcements (FOAs) inviting proposals on HIV prevention, therapeutic, and vaccine networks; laboratory centers; and statistical and data management centers. In May 2019, NIH released a FOA for HIV clinical trial units.

Learn more about the FOAs and the network refinement process with the resources and information available on this site. The following resources may be of particular interest to potential applicants:

For information about the refinement of the HIV clinical trials enterprise, view background, videos and blog posts.

Content last reviewed on May 1, 2019